ProImmune Accelerates Development of Therapeutics with REVEAL™ B Cell Epitope Discovery System
Product News Mar 09, 2009
ProImmune Ltd has launched the REVEAL™ B Cell Epitope Discovery System, a service designed to accelerate the development of biological therapies and understanding of diseases at a structural level.
The REVEAL™ service offers both comprehensive best consensus epitope prediction and rapid high throughput linear epitope mapping in vitro.
REVEAL™ consensus epitope prediction is a key tool in developing incisive hypotheses for downstream in vitro research. The service is based not only on primary sequence and 3D structure, but also incorporates any other additional information about the protein of interest from publicly available sources, and the experience and knowledge of ProImmune’s expert team to provide an intelligent consensus prediction to identify potential epitopes in a protein of interest.
Unlike hard to control assays that rely on recombinant or purified proteins, REVEAL™ linear epitope mapping relies on standardized peptide synthesis, which simplifies and accelerates the measurement of large numbers of samples.
Based on ProArray™ high-content peptide microarrays that can include thousands of peptides, the service provides a turnkey solution for applications such as vaccine subunit discovery, immunogenicity testing, and correlating antibody responses to protein targets with disease onset, progression and outcome.
Dr. Nikolai Schwabe, CEO of ProImmune, said: “The REVEAL™ B Cell Epitope Discovery System perfectly complements our long standing strength in T cell research and allows us to offer a complete solution to our customers for antigen discovery and antigenicity testing.”